Bristol Myers Squibb's Revlimid revenues 2008-2023

Revenue of top product Revlimid from 2008 to 2023

Download
Show detailed source information?
Register for free
Already a member?
Log in
Sources

Use Ask Statista Research Service

Release date

February 2024

Region

Worldwide

Survey time period

2008 to 2023

Supplementary notes

The statistic was assembled from several annual reports.
* Transition year (BMS' acquisition of Celgene); value is rounded.
** Year of first generic version on the market.

Citation formats
Statista Accounts: Access All Statistics. Starting from $2,148 USD / Year
Basic Account
Get to know the platform

You only have access to basic statistics.
This statistic is not included in your account.

Starter Account
The ideal entry-level account for individual users
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references
$199 USD $179 USD / Month *
in the first 12 months
Professional Account
Full access

Business Solutions including all features.

* Prices do not include sales tax.

Statistics on " Top pharmaceutical drugs "

Other statistics that may interest you Top pharmaceutical drugs

Global overview

3

Top companies' top products

5

Best-selling drugs

7

U.S. overview

5

Outlook

5

Further related statistics

19
Statista Accounts: Access All Statistics. Starting from $2,148 USD / Year
Learn more about how Statista can support your business.